ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ProKidney Corp (Nasdaq: PROK), a late clinical-stage biotech company specializing in cell therapy for chronic kidney disease (CKD), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bruce Culleton, M.D., will deliver a presentation on January 15, 2025, at 7:30am PST.
The company's management team will be available for one-on-one meetings during the event. Interested parties can access the live webcast through the 'Events' section of ProKidney's Investor Relations webpage at www.prokidney.com. A replay of the presentation will remain available for 90 days following the event.
ProKidney Corp (Nasdaq: PROK), una biotech in fase clinica avanzata specializzata in terapia cellulare per le malattie renali croniche (CKD), ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il CEO Bruce Culleton, M.D., presenterà il suo intervento il 15 gennaio 2025, alle 7:30 PST.
Il team di gestione dell'azienda sarà disponibile per incontri individuali durante l'evento. Le parti interessate possono accedere al webcast dal vivo tramite la sezione 'Eventi' del sito web delle Relazioni con gli Investitori di ProKidney all'indirizzo www.prokidney.com. La registrazione della presentazione rimarrà disponibile per 90 giorni dopo l'evento.
ProKidney Corp (Nasdaq: PROK), una empresa biotecnológica en etapa clínica avanzada especializada en terapia celular para la enfermedad renal crónica (ERC), ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. El CEO Bruce Culleton, M.D., presentará el 15 de enero de 2025, a las 7:30 a.m. PST.
El equipo directivo de la compañía estará disponible para reuniones uno a uno durante el evento. Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos' de la página web de Relaciones con Inversores de ProKidney en www.prokidney.com. Una repetición de la presentación estará disponible durante 90 días después del evento.
ProKidney Corp (Nasdaq: PROK), 만성 신장 질환(CKD)을 위한 세포 치료에 특화된 임상 단계가 늦은 생명공학 회사가 제43회 J.P. Morgan Healthcare 컨퍼런스에 참여한다고 발표했습니다. CEO 브루스 컬레톤(Dr. Bruce Culleton)은 2025년 1월 15일, 오전 7:30 PST에 발표를 할 예정입니다.
회사의 경영진 팀은 행사 동안 일대일 회의에 참석할 수 있습니다. 관심 있는 당사자는 www.prokidney.com의 ProKidney 투자자 관계 웹페이지의 '이벤트' 섹션을 통해 생중계를 이용할 수 있습니다. 발표의 재생은 행사 후 90일 동안 제공될 것입니다.
ProKidney Corp (Nasdaq: PROK), une entreprise biopharmaceutique en phase clinique avancée spécialisée dans la thérapie cellulaire pour les maladies rénales chroniques (CKD), a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Le PDG Bruce Culleton, M.D., fera une présentation le 15 janvier 2025, à 7h30 PST.
L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles pendant l'événement. Les parties intéressées peuvent accéder au webcast en direct via la section 'Événements' de la page Relations Investisseurs de ProKidney à l'adresse www.prokidney.com. Un enregistrement de la présentation sera disponible pendant 90 jours suivant l'événement.
ProKidney Corp (Nasdaq: PROK), ein spätklinisches Biotech-Unternehmen, das sich auf zellulare Therapie bei chronischen Nierenerkrankungen (CKD) spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt gegeben. CEO Bruce Culleton, M.D., wird am 15. Januar 2025, um 7:30 Uhr PST eine Präsentation halten.
Das Management-Team des Unternehmens steht während der Veranstaltung für Einzelgespräche zur Verfügung. Interessierte Parteien können über den Bereich 'Veranstaltungen' auf der Investor-Relations-Webseite von ProKidney unter www.prokidney.com auf das Live-Webcast zugreifen. Eine Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.
| 43rd Annual J.P. Morgan Healthcare Conference | |
| Date: | January 15, 2025 |
| Time: | 7:30am PST |
| Format: | Presentation |
| Webcast: | Link |
The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the event, a replay will be available for 90 days.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will ProKidney's (PROK) J.P. Morgan Conference presentation replay be available?
Where can investors watch ProKidney's (PROK) J.P. Morgan Healthcare Conference presentation?
What is ProKidney's (PROK) main focus in development?
Will ProKidney (PROK) management be available for individual meetings at the J.P. Morgan Conference?
